CHILDREN'S FLONASE ALLERGY RELIEF OTC
Generic Name and Formulations:
Fluticasone propionate 50mcg; per nasal spray.
Indications for CHILDREN'S FLONASE ALLERGY RELIEF:
Relieves symptoms of hay fever or other upper respiratory allergies.
Initially 2 sprays in each nostril once daily for Week 1, then 1 or 2 sprays in each nostril once daily as needed for Week 2 through 6 months. Reevaluate after 6 months.
<4yrs: not recommended. Use for the shortest duration necessary to achieve response. ≥4yrs: 1 spray in each nostril once daily. Reevaluate after 2 months.
Not for treating asthma. Injury or surgery to nose that is not fully healed: not recommended. Discontinue if exposed to chicken pox, measles, or tuberculosis. Glaucoma. Cataracts. Discontinue if whistling sound from nose, visual disturbances, severe or frequent nosebleeds occur. Discontinue if no improvement within 7 days after starting or if new symptoms (eg, facial pain, nasal discharge) develop. Avoid eyes or mouth. Pregnancy. Nursing mothers.
Caution with concomitant ritonavir, ketoconazole, other steroids.
Stinging, sneezing, headaches, dry/irritated nose or throat, nosebleeds, whistling sound, blurred or reduced vision, reduced growth rate in children, allergic reaction (discontinue if occurs).
Spray—9.9mL (60 sprays), 15.8mL (120 sprays); Children's—2 × 9.9mL (2 × 60 sprays)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC